MEDISENSE BLOOD GLUCOSE MONITORING TEST MANUFACTURER'S UNAUDITED FISCAL 1994 REVENUES ARE UP 18% TO $110.4 MIL.; FIRM HOPES TO NET $55.2 MIL. IN IPO
This article was originally published in The Gray Sheet
Executive Summary
Home blood glucose monitoring systems manufacturer MediSense had fiscal year 1994 (ended March 31) revenues of $110.4 mil., up 18.4% from 1993's revenues of $93.2 mil., VP and Chief Financial Officer John Chiricotti told a May 9 session of Alex. Brown & Sons health care seminar in Baltimore. The 1994 results are preliminary and unaudited, he said.